<DOC>
	<DOCNO>NCT02618434</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy , safety tolerability SPN-810 treatment impulsive aggression patient Attention Deficit/Hyperactivity Disorder ( ADHD ) conjunction standard ADHD treatment . Approximately 291 subject age 6 12 year ADHD comorbid impulsive aggression recruit study . The frequency impulsive aggression behavior assess primary outcome . Additionally , severity improvement impulsive aggression , quality life measure subject caregiver assess use validated scale .</brief_summary>
	<brief_title>Treatment Impulsive Aggression Subjects With ADHD Conjunction With Standard ADHD Treatment ( CHIME 2 )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>Otherwise healthy male female subject , age 6 12 year time screen primary diagnosis ADHD currently receive monotherapy treatment optimize FDAapproved ADHD medication . Impulsive aggression confirm screen use RMOAS Vitiello Aggression Scale . Current lifetime diagnosis epilepsy , major depressive disorder , bipolar disorder , schizophrenia relate disorder , personality disorder , Tourette 's disorder , psychosis otherwise specify . Currently meet DSM criterion autism spectrum disorder , pervasive developmental disorder , obsessive compulsive disorder , posttraumatic stress disorder , anxiety disorder primary diagnosis . Known suspected intelligence quotient ( IQ ) &lt; 70 , suicidality , pregnancy , substance alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>